Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| RES0067483 | Other Identifier | University of Alberta |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Alberta Diabetes Institute | OTHER |
Not provided
Not provided
Not provided
Not provided
This study compares aerobic exercise training performed before breakfast (i.e., in the fasted state) to similar training performed after breakfast in people with type 1 diabetes. Training will take place over 12 weeks.
People with type 1 diabetes (PwT1D) are encouraged to increase their physical activity (PA). Increasing the amount of PA can be difficult, especially for PwT1D who experience barriers to exercise. Therefore, simply recommending that PwT1D preform more exercise may not be the most effective prescription in the long term. Recent short-term studies have s suggest that exercise performed before eating (fasted) causes blood sugars to decrease less or even increase, compared exercise performed after a meal, which usually causes blood sugar to decrease. To date, no long-term study has compared the effects of exercise performed with or without eating beforehand in people with T1D.
This study will compare the effects of 12 weeks of exercise before breakfast compared to 12 weeks of exercise after breakfast. It is expected that exercise before breakfast (i.e., in the fasted state) will lead to larger reductions in overall insulin dose, without the addition of more exercise.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fasted Exercise | Experimental | Exercise training will be performed in the fasted state (i.e., before breakfast). |
|
| Postprandial Exercise | Active Comparator | Exercise will be performed in the postprandial period (i.e., after breakfast) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fasted Exercise | Behavioral | Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold. |
| Measure | Description | Time Frame |
|---|---|---|
| Daily insulin dose (units/kg/day) | Total daily insulin dose (including basal and bolus insulin) will be measured over 7 consecutive days. | From enrolment to the end of the exercise intervention at week 12. |
| Measure | Description | Time Frame |
|---|---|---|
| Continuous glucose monitoring | 24-hour mean glucose (mmol/L) as measured by continuous glucose monitors. | From enrolment to the end of the exercise intervention at week 12. |
| Continuous glucose monitoring |
Not provided
Inclusion Criteria:
Clinical diagnosis of type 1 diabetes for 5 or more years.
Treatment using an insulin pump with no change in treatment modality for > 2 continuous months and willing to share CGM data with the research team. Insulin delivery can be managed using either manual open-loop system (non-AID) or a hybrid closed loop (AID) systems.
Using rapid (e.g., Aspart, Lispro or Glulisine) or ultra-rapid (e.g., FiAsp) acting insulin analogs.
HbA1c 7.0-9.9%.
Have BMI of 25 kg/m2 or above
Have waist circumference associated with central obesity/metabolic syndrome as per Diabetes Canada definition
No history of stroke, myocardial infarction, or coronary artery disease
Not wearing implantable device such as a pacemaker, neurostimulators, aneurysm clips, metal fragments, epicardial electrodes, cochlear implants, magnetic ocular implants, penile implants, magnetic tissue expander, some types of breast implants, magnetic orthopedic implants, magnetic dental implants, hearing Aids, intravascular implants, for example VCI filters, coils, stents, cardiac septum implants, ventricular bypass devices.
Use a CGM in routine diabetes management.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Normand Boule, PhD | Contact | 780-492-4695 | nboule@ualberta.ca | |
| Reid McClure, MSc | Contact | 780-492-8079 | rmcclur1@ualberta.ca |
| Name | Affiliation | Role |
|---|---|---|
| Normand G Boule, PhD | University of Alberta | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alberta | Recruiting | Edmonton | Alberta | T6G 2E1 | Canada |
We plan to share all of the data related to study outcomes pm am open access website through the University of Alberta "Education and Research Archive" (ERA). Individual participant characteristics that could be used to identify participants (age, sex, height, weight) will not be be placed on ERA.
The data will become available one year after the completion of the trial.
The outcome data will be open access through the University of Alberta "Education and Research Archive" (ERA) website. Other participant characteristics will be available as meta-data.
Not provided
Not provided
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| D009043 | Motor Activity |
| D005234 | Fatty Liver |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Pre vs post, 2 group parallel study design
Not provided
Not provided
Not provided
|
| Postprandial Exercise | Behavioral | Participants will complete three sessions of combined resistance-aerobic exercise per week. Sessions will always start with resistance training followed by aerobic training, and will increase in duration throughout the intervention period, so that by the final three weeks of the intervention, all participants accumulate 150 minutes per week of moderate intensity aerobic exercise and 75 minutes of resistance exercise per week. Participants will complete three distinct resistance exercise sessions per week, which will increase in load, but decrease in repetition range throughout the trial. The aerobic component of the exercise sessions will increase in duration from 35 to 50 minutes per session. Participants will walk on a treadmill at a speed and incline that corresponds to 70-80% of ventilatory threshold. |
|
Time in range (%) as measured by continuous glucose monitors.
| From enrolment to the end of the exercise intervention at week 12. |
| Magnetic resonance imaging (MRI) volumes | MRI derived volumes (e.g., muscle fat, hepatic fat, pancreatic fat, subcutaneous fat, visceral fat) | From enrolment to the end of the exercise intervention at week 12. |
| Basal and bolus insulin dose (units/kg/day) | Basal insulin dose (units/kg/day), bolus insulin dose (units/kg/day), and basal to bolus ratio | From enrolment to the end of the exercise intervention at week 12. |
| Bioelectrical impedance (BIA) in kilograms | BIA body composition outcomes (e.g., fat mass, fat free mass, total body water), all measured in kilograms | From enrolment to the end of the exercise intervention at week 12. |
| Glycated haemoglobin (%) | Hlycated hemoglobine (also known as HbA1c) expressed as a percentage. | From enrolment to the end of the exercise intervention at week 12. |
| Concentrations of Fasting glucose | Plasma glucose measured after an overnight fast | From enrolment to the end of the exercise intervention at week 12. |
| Concentrations of Fasting insulin | Plasma insulin measured after an overnight fast | From enrolment to the end of the exercise intervention at week 12. |
| Concentrations of Fasting lipids | Plasma total cholesterol, HDL-Cholesterol, LDL-Cholesterol and Triglycerides measured after an overnight fast | From enrolment to the end of the exercise intervention at week 12. |
| Aerobic fitness | Exercise test to determine ventilatory threshold | From enrolment to the end of the exercise intervention at week 12. |
| Body weight (kilograms) | Weight will be measured in kilograms | From enrolment to the end of the exercise intervention at week 12. |
| Height (centimeters) | Standing height | From enrolment to the end of the exercise intervention at week 12. |
| Waist circumference (centimeters) | Waist circumference (between 12 rib and iliac crest) measures in centimeters | From enrolment to the end of the exercise intervention at week 12. |
| Hip circumference (centimeters) | Hip circumference (between 12 rib and iliac crest) measures in centimeters | From enrolment to the end of the exercise intervention at week 12. |
| Physical Activity in minutes per day | Accelerometer measured active time (min/day), sedentary time (min/day) | From enrolment to the end of the exercise intervention at week 12. |
| Food logs (kilocalories) | Food logs will be completed for three days (two weekday and one weekend) for estimation of macronutrient intake and total energy intake. Each of these will be expressed as kilocalories (i.e., kcal). | From enrolment to the end of the exercise intervention at week 12. |
| Feasibility (rates expressed as percentage of the total sample) | Feasibility will include recruitment rate, and dropout rate. Each rate will be reported as the percentage of the total sample. | From enrolment to the end of the exercise intervention at week 12. |
| Feasibility (rates expressed as percentage of the total number of sessions) | Feasibility will also include exercise adherence. Adherence will be reported as the percentage of the prescribed exercise sessions that were completed). | From enrolment to the end of the exercise intervention at week 12. |
| Feasibility (barriers) | Barriers will bve assessed using the "Barriers to Physical Activity in Type 1 Diabetes" (BAPAD-1) scale. This is a 11-item scale with 7-point Likert-type questions (i.e., each question has a minimum of 1 and a maximum of 7). The maximum score is therefore 77 and minimum score 11. A higher score indicates greater barriers. | From enrolment to the end of the exercise intervention at week 12. |
| D004700 | Endocrine System Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
| D001519 | Behavior |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |